TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8396103
Drug: Erythromycin ethylsuccinate,
Normalized name: Erythromycin Ethylsuccinate, ethylsuccinate compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin ethylsuccinate, 30‐50 mg/kg daily in three divided doses for ten days (n = 47)
Study: 24170106
Drug: LB03002 (once-weekly)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (once-weekly)
Study: 24170106
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (daily)
Study: 24170106
Drug: LB03002 (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB03002 (once-weekly throughout)
Study: 22874850
Drug: Semi-synthetic DTwP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-synthetic DTwP vaccine
Study: 22874850
Drug: Routine DTwP
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine DTwP vaccine
Study: 20517329
Drug: Q‐500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q‐500 (500 mg/day)
Study: 20517329
Drug: Q‐1000 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q‐1000 (1000 mg/day)
Study: 8707025
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg o.d.
Study: 8707025
Drug: Nifedipine AR
Normalized name: nifedipine Extended Release Oral Tablet [Adalat AR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine AR 20 mg b.d.
Study: 1679569
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (azathioprine + sulfasalazine)
Study: 26784000
Drug: Extended ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Extended ofatumumab treatment
Study: 22558609
Drug: Palmitoylethanolamide (PEA)
Normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmitoylethanolamide (PEA) 300 mg in the morning and 600 mg in the evening for 7 days, then 300 mg twice a day for 7 more days
Study: 22558609
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg three times a day for 2 weeks
Study: 12679767
Drug: Tirofiban infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban infusion
Study: 11029126
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg(‐1) cisatracurium
Study: 11029126
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg kg(‐1) cisatracurium
Study: 1305331
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms sublingual GTN
Study: 1305331
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg buccal GTN
Study: 31145432
Drug: Static treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Static treatment protocol
Study: 31145432
Drug: Dynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic treatment protocol
Study: 22334369
Drug: Pioglitazone 30-45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30-45 mg/day plus standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Study: 20803300
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) administered twice daily, titrated from 250 to 2,000 mg/day
Study: 17937961
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg tolterodine extended release
Study: 17937961
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg tolterodine extended release
Study: 7800329
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (1 mg), administered at admission and repeated 6 hours later if labor was not established
Study: 7800329
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (1 mg)
Study: 2181769
Drug: Furosemide administered
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide administered post-TURP
Study: 30587533
Drug: Mupirocin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin (5 days of intranasal plus topical application to the intranasal, periumbilical, and perianal areas)
Study: 30587533
Drug: Mupirocin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin (5 days of intranasal plus topical application)
Study: 12532318
Drug: Temazepam (7.5-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temazepam (7.5-30 mg)
Study: 8652325
Drug: Rocuronium 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 6 mg
Study: 8652325
Drug: Vecuronium 1
Normalized name: vecuronium 10 mg/10 mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 1 mg
Study: 2049961
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg orally once daily for 3 weeks)
Study: 2049961
Drug: Co-trimoxazole (320/1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (320/1,600 mg orally once daily for 3 weeks)
Study: 6388218
Drug: Danazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (100 mg, 2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Study: 6388218
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Study: 25434622
Drug: EMLA® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® cream (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) applied for 60 minutes prior to cryotherapy
Study: 25434622
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied for 60 minutes prior to cryotherapy
Study: 25434622
Drug: EMLA® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® cream (for those with more than 1 wart)
Study: 25434622
Drug: EMLA® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA® cream (for those with only 1 wart)
Study: 23167380
Drug: Rational-Emotive Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-Emotive Behavior Therapy (REBT) for 45 days (ten sessions)
Study: 9934749
Drug: 6 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Study: 9934749
Drug: 9 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 9 MILLION UNT/SYR INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Study: 7594330
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg (n = 9)
Study: 7594330
Drug: lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lansoprazole (LPZ) 30 mg (n = 16)
Study: 7594330
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus plaunotol 480 mg (n = 13)
Study: 7594330
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus ecabet sodium 2 g (n = 11)
Study: 7594330
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11)
Study: 7594330
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13)
Study: 7594330
Drug: LPZ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13)
Study: 23645099
Drug: Calcitriol administration
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol administration (0.25 μg bid for 1 week)
Study: 23645099
Drug: Cholecalciferol (300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (300,000 IU single oral dose)
Study: 20236252
Drug: 360° laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360° laser trabeculoplasty and topical betaxolol eye drops B.I.D.
Study: 11527892
Drug: Albumin administration
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin administration on the day of oocyte retrieval
Study: 11527892
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution (placebo control)
Study: 18649869
Drug: Albumin administration
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin administration
Study: 9085712
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol in light alcohol consumers
Study: 9085712
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg alcohol in light alcohol consumers
Study: 9085712
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg alcohol in moderate alcohol consumers
Study: 9085712
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol in moderate alcohol consumers
Study: 9085712
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg and 1.0 g/kg alcohol in light consumers (frequency and duration measures)
Study: 9085712
Drug: 1.0 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g/kg alcohol in moderate consumers (duration measure)
Study: 7942724
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of quadruple therapy
Study: 7942724
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of quadruple therapy
Study: 2598985
Drug: CI-924 (CI)
Normalized name: CI 77266
DrugBank: Carbon black (DB11980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-924 (CI) 600 mg/day
Study: 788733
Drug: Synthetic isoquinoline
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic isoquinoline compound (U.K. 2371)
Study: 22765645
Drug: High-dose levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levofloxacin 750 mg intravenously once daily, followed by the same dose orally at discharge when clinically improved.
Study: 22765645
Drug: Ceftriaxone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2.0 g intravenously once daily plus oral azithromycin 500 mg for 3 consecutive days, followed by oral cefpodoxime 200 mg per day at discharge after clinical improvement.
Study: 22765645
Drug: High-dose levofloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levofloxacin
Study: 7740334
Drug: Combined doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doxorubicin (50 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1 and 8) every 21 days
Study: 2258080
Drug: Carboplatin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (400 mg/m2 IV every 28 days)
Study: 11326179
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 3 mg (group 1)
Study: 30678863
Drug: Mineralocorticoid Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid Receptor Antagonists (MRA)
Study: 27043452
Drug: MP‐AzeFlu (Dymista(®),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP‐AzeFlu (Dymista(®), 1 spray/nostril bid)
Study: 27043452
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP, 1 spray/nostril bid)
Study: 24281730
Drug: Montelukast (monotherapy)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (monotherapy)
Study: 24281730
Drug: Antihistamine (monotherapy)
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine (monotherapy)
Study: 23200287
Drug: Mentalization-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mentalization-based treatment for adolescents (MBT-A)
Study: 18097903
Drug: Obstetric fistulae
Normalized name: Cassia fistula whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obstetric fistulae treatment
Study: 15800937
Drug: Quetiapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (up to 200 mg daily)
Study: 12450694
Drug: Urease (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urease (60 mg) + LT (5 microg)
Study: 12450694
Drug: Urease (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urease (60 mg) + LT (25 microg)
Study: 12450694
Drug: Urease (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urease (60 mg)
Study: 366085
Drug: Bromocriptine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (30 mg per day in divided doses)
Study: 27880079
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (3 mg/kg)
Study: 23615650
Drug: Watermelon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watermelon supplementation (L‐citrulline/L‐arginine 6 g/d)
Study: 20077977
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi (intervention not specified in dosage or duration)
Study: 12601628
Drug: Troglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone treatment in Group A
Study: 12601628
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in Group B
Study: 12601628
Drug: Troglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone treatment in Groups B and C
Study: 12601628
Drug: Troglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone treatment in all groups
Study: 10553828
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg (2 mL 1.5%)
Study: 10553828
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg (3 mL 1.5%)
Study: 10553828
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg (4 mL 1.5%)
Study: 30457668
Drug: Citicoline (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (titrated to 2,000 mg/d)
Study: 29132478
Drug: Vaginal clindamycin
Normalized name: clindamycin Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal clindamycin (multiple doses)
Study: 29132478
Drug: Oral secnidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral secnidazole (single 2-gm dose)
Study: 21554817
Drug: Whole-grain wheat
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain wheat (48 g daily for 3 weeks)
Study: 10685531
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg/d) on days 3-7 of the CC-treated cycles
Study: 9692707
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily; n = 8)
Study: 9692707
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg b.d.; n = 6)
Study: 9692707
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (before treatment; n = 24)
Study: 25760389
Drug: 5% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glycolic plant extract applied externally (gel cream) for 21 days
Study: 24351403
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no active treatment)
Study: 20099236
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination latanoprost-timolol (n = 170)
Study: 20099236
Drug: Latanoprost monotherapy
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost monotherapy (n = 165)
Study: 20099236
Drug: Timolol monotherapy
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol monotherapy (n = 165)
Study: 18402906
Drug: SR123781A 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR123781A 0.25 mg
Study: 18402906
Drug: SR123781A 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR123781A 0.5 mg
Study: 18402906
Drug: SR123781A 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR123781A 1.0 mg
Study: 18402906
Drug: SR123781A 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR123781A 2.0 mg
Study: 18402906
Drug: SR123781A 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR123781A 4.0 mg
Study: 18402906
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg (calibrator arm)
Study: 12386357
Drug: Intratubal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratubal methotrexate 1 mg/kg
Study: 10458218
Drug: Vorozole (VOR)
Normalized name: vorozole
DrugBank: Vorozole (DB13767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole (VOR) 2.5 mg once daily
Study: 10458218
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) 40 mg four times per day
Study: 7605361
Drug: Kwai garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kwai garlic powder tablets 300 mg three times daily
Study: 7119301
Drug: Budesonide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (various doses), morning dosing
Study: 7119301
Drug: Budesonide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (various doses), reduced dose frequency
Study: 27060731
Drug: Intervention manipulations
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention manipulations (either of the intervention manipulation or combination)
Study: 22406033
Drug: Sleep hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep hygiene therapy
Study: 17947598
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (0.2 g/kg/d of nitrogen and 30 nonprotein kcal/kg/d)
Study: 17947598
Drug: Standard hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hospital oral diet (control group)
Study: 15939923
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) 2.6 g/m(2) and folinic acid (FA) 500 mg/m(2) weekly for 6 weeks followed by a 2-week rest (AIO arm, n = 216)
Study: 15939923
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) 2.3 or 2.0 g/m(2) preceded by irinotecan 80 mg/m(2) administered over 30 minutes weekly for 6 weeks followed by a 2-week rest (experimental group, n = 214)
Study: 10456819
Drug: Single-injection paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection paravertebral block at the level of T4
Study: 2357777
Drug: Intravenous potassium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous potassium chloride (Group I, 44 patients)
Study: 2357777
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (Group II, 48 patients)
Study: 2357777
Drug: Oral potassium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral potassium chloride capsules (Group III, 50 patients)
Study: 2357777
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (Group IV, 47 patients)
Study: 26518
Drug: Proglumide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proglumide (1200 mg per day for 28 days)
Study: 26518
Drug: Cimetidine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1200 mg per day for 28 days)
Study: 31568387
Drug: Plantar flexor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plantar flexor strengthening associated with conventional physical therapy treatment
Study: 31568387
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treatment (gait training, triceps surae muscle stretching, anterior tibial muscle strengthening, and motor sensory training)
Study: 15625071
Drug: Gentamicin cream
Normalized name: gentamicin Topical Cream
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentamicin cream
Study: 19019257
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol or sterol ester (2 g)
Study: 17682990
Drug: Zinc nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc nasal gel
Study: 17682990
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges or nasal spray
Study: 16405839
Drug: Cytokines absorption
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines absorption using sulfonated polyacrylonitrile hemofilter (AN69)
Study: 12021824
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg caffeine
Study: 6436891
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg caffeine
Study: 8533175
Drug: Minimal exercise
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal exercise (twice weekly for three months)
Study: 2080308
Drug: UDPG (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDPG (400 mg/im/die for 30 days)
Study: 26446726
Drug: Home-based Parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Parent-child Interaction Therapy (PCIT)
Study: 23875989
Drug: Proactive retention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive retention strategies including obtaining extensive contact information, building relationships with case managers and social workers, contacting jails and prisons, text messaging, e-mailing, messaging via social networking sites, identifying appointments via electronic medical record, and field outreach to treatment facilities, residences, and parks.